These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7768787)

  • 1. In-vitro and in-vivo selection of Staphylococcus aureus mutants resistant to ciprofloxacin.
    Doss SA; Tillotson GS; Barg NL; Amyes SG
    J Antimicrob Chemother; 1995 Jan; 35(1):95-102. PubMed ID: 7768787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
    Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.
    Barry AL; Pfaller MA; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):243-6. PubMed ID: 1317799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
    Richards RM; Hamilton VE; Thomas MR
    J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.
    Perronne CM; Malinverni R; Glauser MP
    Antimicrob Agents Chemother; 1987 Apr; 31(4):539-43. PubMed ID: 3606060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
    Patel MV; De Souza NJ; Gupte SV; Jafri MA; Bhagwat SS; Chugh Y; Khorakiwala HF; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4754-61. PubMed ID: 15561853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.
    Blumberg HM; Rimland D; Carroll DJ; Terry P; Wachsmuth IK
    J Infect Dis; 1991 Jun; 163(6):1279-85. PubMed ID: 2037793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.
    Ince D; Hooper DC
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2755-64. PubMed ID: 11557465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance.
    Didier JP; Villet R; Huggler E; Lew DP; Hooper DC; Kelley WL; Vaudaux P
    Antimicrob Agents Chemother; 2011 May; 55(5):1946-52. PubMed ID: 21357297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Staphylococcus aureus Tet38 native efflux pump on in vivo response to tetracycline in a murine subcutaneous abscess model.
    Chen C; Hooper DC
    J Antimicrob Chemother; 2018 Mar; 73(3):720-723. PubMed ID: 29216347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.
    Campion JJ; McNamara PJ; Evans ME
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4733-44. PubMed ID: 15561851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.